GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

U.K.-based biopharmaceutical company GSK plc (GSK) said on Friday that the European Medicines Agency (EMA) has accepted its ...

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

AREXVY is not approved for use in persons <50 years of age Vaccination with AREXVY may not result in protection of all vaccine recipients Please see full Prescribing Information for AREXVY.

Cumulatively, the efficacy of a single Arexvy dose to prevent RSV-related lower respiratory tract disease over three RSV seasons was 62.9%. Efficacy over three seasons was 51.1%.

AREXVY is not approved for use in persons <50 years of age Vaccination with AREXVY may not result in protection of all vaccine recipients Please see full Prescribing Information for AREXVY.

Abrysvo or Arexvy Market Regional and Country Analysis 10.1. Global Abrysvo or Arexvy Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million 10.2.